{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"description":"BPI is assessed by 7 questions rated \"0\" for \"no pain\" and higher numbers indicated more pain.","groups":[{"description":"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 milligram per square meter (mg/m\\^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG000","title":"100 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG001","title":"300 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Placebo administered once IV on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG002","title":"Placebo Comparator: Placebo + Dexamethasone + Bortezomib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline through End of Treatment (19 months)","title":"Number of Participants With >30% Reduction in Brief Pain Inventory (BPI) - Worst Pain Score","type":"SECONDARY","unitOfMeasure":"Participants"}